12.1 Therapeutic Drug Monitoring and Precision Pharmacokinetics

Therapeutic Drug Monitoring and Precision Pharmacokinetics

Therapeutic drug monitoring (TDM) and precision pharmacokinetics (PK) represent essential clinical competencies in infectious diseases pharmacotherapy. Applying individualized pharmacokinetic/pharmacodynamic (PK/PD) principles maximizes microbial eradication, prevents emergence of resistant subpopulations, and protects patients against concentration-dependent organ toxicities. In critical illness, pathophysiologic shifts—including extreme capillary leak, massive fluid resuscitation, fluctuating protein binding, hypermetabolic hepatic clearance, and augmented renal clearance (ARC)—make standardized population dosing regimens unreliable, mandating patient-specific precision dosing.

---

Vancomycin Precision TDM: The 2020 Consensus Guidelines

For more than a decade, clinical practice adhered to the 2009 vancomycin consensus guidelines, which endorsed surrogate trough concentrations of 15 to 20 mcg/mL for serious methicillin-resistant Staphylococcus aureus (MRSA) infections (bacteremia, endocarditis, osteomyelitis, hospital-acquired pneumonia, and meningitis). However, extensive clinical and pharmacometric evidence demonstrated that trough concentrations correlate poorly with total drug exposure (area under the 24-hour concentration-time curve, $AUC_{24}$) and markedly overestimate the dose required for therapeutic efficacy, driving unacceptable rates of acute kidney injury (AKI).

The Paradigm Shift: AUC-Guided Monitoring

The 2020 updated consensus guidelines published jointly by the American Society of Health-System Pharmacists (ASHP), Infectious Diseases Society of America (IDSA), Pediatric Infectious Diseases Society (PIDS), and Society of Infectious Diseases Pharmacists (SIDP) officially abandoned trough-only monitoring for serious MRSA infections, establishing the following standard of care:

• Primary PK/PD Target: A 24-hour area under the curve to minimum inhibitory concentration ratio ($AUC_{24}/MIC$) of 400 to 600 mg·h/L, assuming a broth microdilution (BMD) MIC of $1\text{ mcg/mL}$ (or $1\text{ mg/L}$).
• Target Attainment and MIC Considerations: An $AUC_{24}/MIC$ of 400 to 600 mg·h/L achieves maximal bactericidal activity while minimizing nephrotoxicity. When the BMD MIC is $< 1\text{ mcg/mL}$, clinicians should not decrease the dose to target an AUC $< 400\text{ mg}\cdot\text{h/L}$, as total exposure must remain therapeutic. Conversely, if the BMD MIC is $> 1\text{ mcg/mL}$ (e.g., $2\text{ mcg/mL}$), achieving an $AUC_{24}/MIC \ge 400$ would require an $AUC_{24} \ge 800\text{ mg}\cdot\text{h/L}$, which carries an unacceptably high risk of severe nephrotoxicity. In such cases, an alternative MRSA agent (e.g., daptomycin, ceftaroline) should be selected.
• Nephrotoxicity Threshold: Sustained vancomycin $AUC_{24} > 600\text{ mg}\cdot\text{h/L}$ or trough concentrations $> 15–20\text{ mcg/mL}$ are independently associated with a 3- to 4-fold increase in acute kidney injury. Trough-guided dosing frequently pushes patients to $AUC_{24}$ values of 700 to 900 mg·h/L to achieve a trough of 15 to 20 mcg/mL, causing avoidable iatrogenic renal damage.

                               VANCOMYCIN PK/PD EXPOSURE SPECTRUM

   AUC24 < 400 mg·h/L             AUC24 400 – 600 mg·h/L             AUC24 > 600 mg·h/L
◄───────────────────────────┼─────────────────────────────────┼───────────────────────────►
   SUBTHERAPEUTIC ZONE               OPTIMAL THERAPEUTIC WINDOW              TOXIC ZONE
 • Clinical failure risk          • Maximal MRSA bactericidal killing    • Steep rise in AKI
 • Selection of VISA/hVISA        • Broth microdilution MIC = 1 mg/L     • Proximal tubular necrosis
 • Prolonged bacteremia           • Minimal risk of nephrotoxicity       • Complement-mediated damage

Analytical Methods for AUC Estimation

The 2020 guidelines endorse two scientifically validated methodologies for calculating vancomycin $AUC_{24}$:

1. Bayesian Estimation Software (Preferred):
   • Utilizes rich, previously validated population PK models as the "prior" distribution, combined with one or two patient-specific measured concentrations (the "likelihood") to generate the Maximum A Posteriori (MAP) Bayesian estimate of individual PK parameters ($V_d$ and clearance).
   • Operational Advantages: Samples do not require strict steady-state conditions; concentrations can be obtained within the first 24 to 48 hours of therapy. A single concentration (e.g., a 12- to 24-hour post-load concentration or trough) is often sufficient in hemodynamically stable patients, although two concentrations (a post-distribution peak at 1–2 hours post-infusion and a pre-dose trough) provide the highest predictive accuracy in fluctuating critically ill patients.
2. First-Order Analytic Pharmacokinetic Equations (Alternative):
   • Employ standard 2-point kinetic equations to calculate individual elimination rate constant ($k_e$) and volume of distribution ($V_d$) at steady state.
   • Sampling Requirements: Strictly requires two concentrations obtained at steady state (typically prior to the 4th or 5th dose):
     • Peak concentration ($C_{max}$): Drawn 1 to 2 hours after completion of the intravenous infusion (to permit complete distribution out of the central vascular compartment into peripheral tissues).
     • Trough concentration ($C_{min}$): Drawn within 30 minutes prior to the administration of the next scheduled dose.
   • Mathematical Implementation:
     • Elimination rate constant: $k_e = \frac{\ln(C_{peak} / C_{trough})}{\Delta t}$
     • Peak at end of infusion: $C_{max} = \frac{C_{peak}}{e^{-k_e \cdot t'}}$ (where $t'$ is the time between end of infusion and peak draw)
     • Trough immediately prior to dose: $C_{min} = C_{trough} \cdot e^{-k_e \cdot t''}$ (where $t''$ is time between trough draw and next dose)
     • 24-hour AUC: $AUC_{24} = \left( \frac{C_{max} + C_{min}}{2} \times t_{inf} + \frac{C_{max} - C_{min}}{k_e} \right) \times \left( \frac{24}{\tau} \right)$

---

Aminoglycosides TDM: Gentamicin, Tobramycin, and Amikacin

Aminoglycosides exhibit concentration-dependent bactericidal activity, meaning the rate and extent of bacterial eradication correlate directly with the ratio of peak drug concentration to minimum inhibitory concentration ($C_{max}/MIC$). Furthermore, aminoglycosides display a prolonged post-antibiotic effect (PAE), suppressing bacterial regrowth for several hours even after serum concentrations drop well below the MIC.

Pharmacodynamic Targets

• Target $C_{max}/MIC$ Ratio: An optimal clinical response requires a $C_{max}/MIC \ge 8–10$ (ideally 10 to 12) at the site of infection. This high peak-to-MIC ratio rapidly sterilizes tissue, overcomes low-level adaptive resistance, and prevents mutational emergence.
• Nephrotoxicity and Ototoxicity Dynamics: Aminoglycoside nephrotoxicity (acute tubular necrosis, non-oliguric) results from saturable, receptor-mediated pinocytosis by megalin/cubilin complexes in the brush border of renal proximal tubular cells. The drug is sequestered in secondary lysosomes, forming myeloid bodies, inhibiting phospholipases, and provoking cellular necrosis.
• Renal Cortical Washout: Because megalin uptake is saturable at low concentrations, administering a single, large daily dose saturates the uptake receptors quickly. When serum concentrations drop below threshold levels for a prolonged period each day, passive clearance ("washout") of aminoglycosides from the renal parenchyma occurs, significantly mitigating nephrotoxicity.

                         EXTENDED-INTERVAL AMINOGLYCOSIDE STRATEGY

 Concentration (mcg/mL)
    ▲
 20 ┼──────┐ High Cmax/MIC (≥ 10:1)
    │      │ Rapid, concentration-dependent killing
 15 ┼       \
    │        \
 10 ┼         \
    │          \  Prolonged Post-Antibiotic Effect (PAE)
  5 ┼           \
    │            \  Hartford Nomogram (6–14h single level)
  1 ┼             \────────────────────────────────────────── Undetectable Trough (< 0.5–1 mcg/mL)
  0 ┴───────┬──────────────┬──────────────┬──────────────┬──────────────► Time (hours)
           Infusion        8h             16h            24h
                          ◄── Renal Tubular Washout Window ──►

Dosing Strategies: Extended-Interval vs. Traditional Intermittent

1. Extended-Interval Dosing (Once-Daily Dosing):
   • Dosing Regimen: Gentamicin or Tobramycin 5 to 7 mg/kg IV once daily (Amikacin 15 to 20 mg/kg IV once daily), calculated using ideal body weight (IBW), or adjusted body weight (ABW) if actual weight is $> 120\%$ of IBW.
   • Monitoring (The Hartford Nomogram): A single random serum concentration is obtained between 6 and 14 hours after the start of the first infusion. The concentration is plotted on the Hartford nomogram to dictate the dosing interval: every 24 hours, every 36 hours, or every 48 hours. If the level falls on the dividing line, the longer interval is selected. If the concentration is below the 24-hour line, q24h dosing is maintained.
   • Trough Target: Trough concentrations drawn immediately prior to the next scheduled dose must be undetectable or $< 0.5–1\text{ mcg/mL}$ for gentamicin/tobramycin ($< 1–2\text{ mcg/mL}$ for amikacin) to guarantee adequate renal cortical clearance.
   • Exclusions: Extended-interval dosing is contraindicated in end-stage renal disease ($CrCl < 20–30\text{ mL/min}$), ascites or massive volume overload, burns involving $> 20\%$ total body surface area, pregnancy, and enterococcal infective endocarditis synergy.
2. Traditional Intermittent Dosing:
   • Dosing Regimen: Gentamicin or Tobramycin 1.5 to 2 mg/kg IV every 8 hours (Amikacin 5 to 7.5 mg/kg IV every 8 hours).
   • Therapeutic Targets:
     • Gram-Negative Bacteremia/Sepsis: Peak 6 to 10 mcg/mL, Trough $< 2\text{ mcg/mL}$.
     • Pneumonia (Pseudomonas): Peak 8 to 12 mcg/mL (due to poor epithelial lining fluid penetration), Trough $< 2\text{ mcg/mL}$.
     • Amikacin: Peak 20 to 30 mcg/mL, Trough $< 5\text{ mcg/mL}$.
3. Gram-Positive Synergy Dosing (Enterococcal or Staphylococcal Endocarditis):
   • Used in combination with a cell-wall active agent (ampicillin, penicillin, ceftriaxone, or vancomycin) to breach the bacterial peptidoglycan envelope, allowing aminoglycoside entry to target the 30S ribosomal subunit.
   • Regimen: Gentamicin 1 mg/kg IV every 8 hours (or 3 mg/kg IV once daily for select streptococcal endocarditis).
   • Synergy Targets: Peak 3 to 4 mcg/mL, Trough $< 1 mcg/mL$.

---

Antifungal Therapeutic Drug Monitoring

Therapeutic drug monitoring is standard clinical practice for mold-active triazoles and flucytosine due to unpredictable bioavailability, saturable metabolism, significant pharmacogenomic polymorphisms, and narrow therapeutic windows.

Voriconazole

Voriconazole is the primary agent of choice for invasive pulmonary aspergillosis and scedosporiosis. It displays complex, non-linear (dose-dependent) Michaelis-Menten pharmacokinetics in adults, meaning that small dosage increases can precipitate disproportionately large increases in serum concentrations due to metabolic saturation of hepatic enzymes.

• Pharmacogenomics: Voriconazole is extensively metabolized by CYP2C19 (and to a lesser degree CYP2C9 and CYP3A4). Genetic polymorphisms dramatically alter exposure:
  • *CYP2C19 Poor Metabolizers (*2, 3 alleles): Experience 4-fold higher circulating drug concentrations and elevated toxicity risk (prevalence ~15–20% in East Asians, ~3–5% in Caucasians and Africans).
  • *CYP2C19 Rapid/Ultrarapid Metabolizers (17 allele): Exhibit accelerated clearance and high rates of subtherapeutic levels, risking breakthrough invasive fungal infection.
• Therapeutic Trough Target: 1.5 to 5.5 mcg/mL at steady state (drawn on day 4 to 7 of therapy, prior to dose administration).
  • Trough $< 1.0–1.5\text{ mcg/mL}$: Strongly correlated with therapeutic failure and breakthrough fungal infection.
  • Trough $> 5.5\text{ mcg/mL}$: Associated with severe concentration-dependent neurotoxicity (visual hallucinations, confusion, altered mental status, encephalopathy), QTc prolongation, and hepatotoxicity (cholestatic and hepatocellular transaminase elevation).
  • Long-Term Adverse Events: Chronic voriconazole exposure is linked to fluorosis and painful nodular periostitis (secondary to fluoride accumulation from the voriconazole molecule) and aggressive squamous cell carcinoma of the skin (photosensitivity reaction).

Posaconazole

Posaconazole is indicated for invasive fungal prophylaxis in acute myeloid leukemia/myelodysplastic syndromes and graft-versus-host disease (GVHD), as well as salvage treatment of invasive aspergillosis and mucormycosis.

• Formulation Differences:
  • Oral Suspension: Characterized by erratic, saturable absorption. Requires co-administration with a high-fat meal or acidic carbonated beverage, divided three to four times daily. Serum concentrations are blunted by proton pump inhibitors (PPIs) and H2-receptor antagonists.
  • Delayed-Release (DR) Tablets and IV Formulation: Provide superior, predictable bioavailability; absorbed in the small intestine independently of gastric pH or dietary fat intake. Tablets have largely replaced the oral suspension in clinical practice.
• Therapeutic Trough Targets:
  • Prophylaxis: Target trough $> 1.0 mcg/mL$ (historically $> 0.7\text{ mcg/mL}$, but modern guidelines favor $> 1.0\text{ mcg/mL}$).
  • Treatment of Invasive Infection: Target trough $> 1.5–2.0 mcg/mL$.
  • Upper Safety Limit: Concentrations $> 3.5–4.0\text{ mcg/mL}$ have been associated with pseudohyperaldosteronism (secondary to $11\beta$-hydroxysteroid dehydrogenase 2 inhibition, causing hypertension, hypokalemia, and metabolic alkalosis).

Itraconazole

Used for histoplasmosis, blastomycosis, and allergic bronchopulmonary aspergillosis (ABPA).

• Formulations: Capsules require gastric acidity and food for dissolution; oral cyclodextrin solution has 30% higher bioavailability and must be taken on an empty stomach.
• Trough Target: $> 1.0–2.0 mcg/mL$ (measured by high-performance liquid chromatography [HPLC]). If measured by bioassay, values appear 2- to 4-fold higher due to the presence of the active hydroxy-itraconazole metabolite.

Flucytosine (5-FC)

Flucytosine is an oral pyrimidine analog co-administered with amphotericin B for cryptococcal meningitis and severe Candida endophthalmitis/endocarditis. It is renally eliminated via glomerular filtration.

• Peak Trough Target: A 2-hour post-dose peak concentration of 25 to 100 mcg/mL (ideally 40 to 80 mcg/mL) must be maintained at steady state.
• Toxicity Threshold: Sustained peak concentrations $> 100 mcg/mL$ lead to life-threatening bone marrow suppression (severe leukopenia, thrombocytopenia, aplastic anemia) and hepatotoxicity. Frequent monitoring is mandatory, especially when renal function fluctuates under amphotericin B co-administration.

Isavuconazole

Isavuconazole (administered as the prodrug isavuconazonium sulfate) possesses linear pharmacokinetics, predictable oral bioavailability (98%), and a wide therapeutic index. Routine TDM is not currently mandated in clinical practice, though levels can be considered for compliance verification or therapeutic failure.

---

Other Critical Antimicrobials Requiring Monitoring

Polymyxin B and Colistin

Polymyxins serve as last-line agents for carbapenem-resistant Gram-negative organisms (Acinetobacter baumannii, Pseudomonas aeruginosa, and carbapenem-resistant Enterobacterales [CRE]).

• Colistin (Colistimethate Sodium, CMS): CMS is an inactive polyanionic prodrug cleared predominantly by renal glomerular filtration. In the body, CMS slowly hydrolyzes into active colistin, which is cleared non-renally. In patients with good renal function ($CrCl > 80\text{ mL/min}$), up to 70–80% of CMS is excreted in urine before converting to active colistin, resulting in subtherapeutic serum concentrations and therapeutic failure.
• Polymyxin B: Administered directly as the active antimicrobial entity; eliminated primarily by non-renal pathways. Pharmacokinetics are significantly more predictable than colistin, with lower interpatient variability in serum AUC.
• TDM Target: Consensus guidelines recommend targeting a steady-state average plasma concentration ($C_{ss,avg}$) of $2\text{ mg/L}$, which equates to an $AUC_{ss,24} \approx 50\text{ mg}\cdot\text{h/L}$. Exposure exceeding an $AUC_{ss,24}$ of 50 to 60 mg·h/L or $C_{ss,avg} > 2.5–3.0\text{ mg/L}$ precipitates severe acute tubular necrosis and non-depolarizing neuromuscular blockade (respiratory arrest).

Linezolid

Although routine TDM is not universally implemented, linezolid exposure varies widely in critically ill septic patients, renal failure, and hepatic cirrhosis. Linezolid exhibits time-dependent killing with an $AUC_{24}/MIC$ target of 80 to 120.

• Trough Target: Maintain steady-state trough between 2 and 7 mcg/mL.
• Toxicity Threshold: Sustained trough levels $> 7–8 mcg/mL$ correlate with marked mitochondrial protein synthesis inhibition, resulting in severe thrombocytopenia, peripheral/optic neuropathy, and lactic acidosis.

Beta-Lactam TDM in Critical Illness

Beta-lactams display time-dependent bactericidal activity, parameterized by the percentage of the dosing interval that unbound (free) drug concentrations remain above the minimum inhibitory concentration ($\% fT > MIC$). While $40–70\% fT > MIC$ is sufficient in outpatient non-severe infections, critically ill patients in the ICU often require:

• Aggressive ICU PK/PD Targets: $100\% fT > MIC$ or even $100\% fT > 4 \times MIC$ (particularly for deep pulmonary infections and high-inoculum sepsis).
• Augmented Renal Clearance (ARC): Defined as measured urinary creatinine clearance $> 130\text{ mL/min}/1.73\text{ m}^2$, frequently seen in young trauma, sepsis, and burn patients. ARC produces rapid clearance of hydrophilic beta-lactams (piperacillin, cefepime, meropenem), resulting in subtherapeutic troughs in up to 50–80% of standard intermittent regimens. Continuous or extended infusions guided by beta-lactam TDM are increasingly utilized to overcome this deficit.